In This Article:
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Cosmo Lady (China) Holdings and Sino Biopharmaceutical are deemed to be superior in terms of how much they’re expected to earn and return to shareholders, according to analysts. If a buoyant growth prospect is what you’re after in your next investment, I’ve put together a list of high-growth stocks you may be interested in, based on the latest financial data from each company.
Cosmo Lady (China) Holdings Company Limited (SEHK:2298)
Cosmo Lady (China) Holdings Company Limited, an investment holding company, engages in the design, research, development, and sale of branded intimate wear products in the People‘s Republic of China. Established in 1998, and run by CEO Yaonan Zheng, the company size now stands at 7,250 people and with the stock’s market cap sitting at HKD HK$10.16B, it comes under the large-cap category.
2298’s projected future profit growth is a robust 21.62%, with an underlying 24.11% growth from its revenues expected over the upcoming years. Profit growth, coupled with top-line expansion, is a positive indication. This is because net income isn’t artificially inflated by unsustainable activities such as one-off cost-reductions expected in the future. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a positive return on equity of 13.40%. 2298’s bullish prospects on both the top and bottom lines make it an interesting stock to invest more time to understand how it can add value to your portfolio. A potential addition to your portfolio? Other fundamental factors you should also consider can be found here.
Sino Biopharmaceutical Limited (SEHK:1177)
Sino Biopharmaceutical Limited, researches, develops, manufactures, and markets Chinese medicines and chemical medicines in Hong Kong. Founded in 2000, and headed by CEO Ping Tse, the company employs 18,649 people and with the company’s market cap sitting at HKD HK$140.70B, it falls under the large-cap stocks category.
1177’s projected future profit growth is a robust 19.31%, with an underlying 67.42% growth from its revenues expected over the upcoming years. It appears that 1177’s profitability may be sustainable as the fundamental push is top-line expansion rather than unmaintainable cost-cutting activities. This prospective profitability should trickle down to shareholders, with analysts expecting the company to generate a high double-digit return on equity of 23.85%. 1177 ticks the boxes for high-growth generation on all levels of line items, which makes it an appealing stock to dig into deeper. Considering 1177 as a potential investment? I recommend researching its fundamentals here.